Friday, December 06, 2024 9:21:17 PM
Just my opinion, of course.
Recent CVM News
- CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer • Business Wire • 01/14/2025 02:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/13/2025 09:16:33 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/03/2025 10:25:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 07:25:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 07:18:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 07:12:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2024 09:15:35 PM
- CEL-SCI Announces Closing of $5 Million Offering • Business Wire • 12/31/2024 09:05:00 PM
- CEL-SCI Announces Pricing of $5 Million Public Offering • Business Wire • 12/30/2024 01:41:00 AM
- CEL-SCI Announces Proposed Public Offering of Common Stock • Business Wire • 12/27/2024 10:05:00 PM
- CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study • Business Wire • 12/12/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2024 09:30:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2024 01:30:30 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/08/2024 05:15:11 AM
- U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025 • Business Wire • 11/07/2024 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/30/2024 09:21:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/25/2024 09:17:48 PM
- FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients • Business Wire • 10/22/2024 01:15:00 PM
- Form AW - Amendment Withdrawal Request • Edgar (US Regulatory) • 10/10/2024 08:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 01:13:25 PM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM
VOCODIA HOLDINGS INC. (OTCMKTS: VHAI) and TRACCOM INC. (OTCMKTS: TRCC) have signed an MOU to form a Joint Venture that will Revolutionize Event Monitoring with Narrative AI • VHAI • Jan 15, 2025 2:53 PM
UAV Corp (OTC: UMAV) Engages Legal Counsel to Initiate Uplisting Process with Ultimate Goal of NASDAQ Listing • UMAV • Jan 15, 2025 8:30 AM
HealthLynked Welcomes Jeremy Daniel as Chief Financial Officer • HLYK • Jan 15, 2025 8:00 AM
Zefiro Methane Corp. Subsidiary Awarded Slate of Government of Ohio-Funded Environmental Remediation Projects • ZEFI • Jan 15, 2025 7:33 AM